Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Rectal Neoplasms 3Barrett Esophagus 2Adenocarcinoma Of Esophagus 2Squamous Cell Carcinoma of Head and Neck 1Pathologic Complete Response 1Ovarian Neoplasms 1Hematologic Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Colonic Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Adenocarcinoma 1

Interventions

Cyclophosphamide 15fludarabine 12Mycophenolic Acid 10Standard of Care 9venetoclax 7Whole-Body Irradiation 7Tacrolimus 7Specimen Handling 7Sirolimus 6Practice Guidelines as Topic 6trametinib 5Melphalan 5Azacitidine 5fludarabine phosphate 4Mesna 4Magnetic Resonance Spectroscopy 4Filgrastim 4Biopsy 4Behavior Therapy 4Thiotepa 3Surveys and Questionnaires 3Peripheral Blood Stem Cell Transplantation 3Interviews as Topic 3GSK2636771 3Educational Status 3Cytarabine 3Crizotinib 3Busulfan 3thymoglobulin 2talquetamab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Endoscopy × 90 days × Clear all
NCT05660421 2026-04-27

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡